ReviewTranslational research : the journal of laboratory and clinical medicine2012
Role of advanced glycation endproducts and glyoxalase I in diabetic peripheral sensory neuropathy.
Review in Translational research : the journal of laboratory and clinical medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
62 citing papers in PubMed, 1 synthesis or guideline pooled it, 135 citations in OpenAlex.
- Therapeutic Interventions to Improve Static Balance in Type 2 DiabetesMellitus: A Systematic Review and Meta-Analysis.Current diabetes reviews · 2024Pooled it
- Trial
- Low-Frequency Electroacupuncture versus Sham Electroacupuncture for Diabetic Peripheral Neuropathy: Study Protocol for a Randomized Controlled Trial.Diabetes, metabolic syndrome and obesity : targets and therapy · 2026Article
- Inflammatory and neurotoxic risk of atorvastatin in diabetic peripheral neuropathy: TNF-centered evidence integrating network toxicology, scRNA-Seq, and cell validation.Frontiers in chemistry · 2026Article
- Unravelling the pathophysiology of diabetic foot ulcer: insights into a complex wound healing process.Frontiers in clinical diabetes and healthcare · 2026Review
- The analgesic effects of insulin and its disorders in streptozotocin-induced short-term diabetes.Physiological reports · 2024Article
- Diabetic Neuropathy: An Overview of Molecular Pathways and Protective Mechanisms of Phytobioactives.Endocrine, metabolic & immune disorders drug targets · 2024Review
- Association between interleg systolic blood pressure difference and apparent peripheral neuropathy in US adults with diabetes: a cross-sectional study.Journal of health, population, and nutrition · 2023Article
- Stem Cell Therapy in Diabetic Polyneuropathy: Recent Advancements and Future Directions.Brain sciences · 2023Review
- Diabetic peripheral neuropathy and their associations with overweight/obesity and impaired blood glucose among diabetic patients in Eastern Ethiopia: Institutional-based study.SAGE open medicine · 2023Article
- Methylglyoxal in the Brain: From Glycolytic Metabolite to Signalling Molecule.Molecules (Basel, Switzerland) · 2022Review
- Is metformin a possible treatment for diabetic neuropathy?Journal of diabetes · 2022Review
- Advanced Glycation End Products and Their Effect on Vascular Complications in Type 2 Diabetes Mellitus.Nutrients · 2022Review
- Dicarbonyl Stress in Diabetic Vascular Disease.International journal of molecular sciences · 2022Review
- In Vitro Methodologies to Study the Role of Advanced Glycation End Products (AGEs) in Neurodegeneration.Nutrients · 2022Review
- Advanced glycation end-products are associated with diabetic neuropathy in young adults with type 1 diabetes.Frontiers in endocrinology · 2022Article
- New horizons of biomaterials in treatment of nerve damage in diabetes mellitus: A translational prospective review.Frontiers in endocrinology · 2022Review
- Design, Synthesis and Biological Evaluation of 1,4-Benzenesulfonamide Derivatives as Glyoxalase I Inhibitors.Drug design, development and therapy · 2022Article
- Treatment for Diabetic Peripheral Neuropathy: What have we Learned from Animal Models?Current diabetes reviews · 2022Review
- Article
2 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Diabetic neuropathy is the most common and debilitating complication of diabetes mellitus with more than half of all patients developing altered sensation as a result of damage to peripheral sensory neurons. Hyperglycemia results in altered nerve conduction velocities, loss of epidermal innervation, and development of painful or painless signs and symptoms in the feet and hands. Current research has been unable to determine whether a patient will develop insensate or painful neuropathy or be protected from peripheral nerve damage all together. One mechanism that has been recognized to have a role in the pathogenesis of sensory neuron damage is the process of reactive dicarbonyls forming advanced glycation endproducts (AGEs) as a direct result of hyperglycemia. The glyoxalase system, composed of the enzymes glyoxalase I (GLO1) and glyoxalase II, is the main detoxification pathway involved in breaking down toxic reactive dicarbonyls before producing carbonyl stress and forming AGEs on proteins, lipids, or nucleic acids. This review discusses AGEs, GLO1, their role in diabetic neuropathy, and potential therapeutic targets of the AGE pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.